Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 4/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.33 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.33 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.33 |
| ▸ | DPP4 | P27487 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | KCNK13 | Q9HB14 | 1/20 | 0.32 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.32 |
| ▸ | GNRHR | P30968 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL639315 | 0.86 | FFAR1 (0.37) | FFAR1PDE10AADORA2AADORA1PLA2G2A | |
| SCHEMBL639218 | 0.85 | BRD4 (0.36) | FFAR1FGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL639125 | 0.82 | KCNN4 (0.41) | FFAR1PDE10AADORA1KCNK13PLA2G2A | |
| SCHEMBL10085137 | 0.78 | FFAR1 (0.37) | FFAR1FGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL2907759 | 0.73 | PLA2G2A (0.43) | MAPTPLA2G2A | |
| SCHEMBL2905371 | 0.72 | POLB (0.46) | PLA2G2A | |
| SCHEMBL2902355 | 0.71 | HTT (0.44) | MAPTPLA2G2A | |
| SCHEMBL638972 | 0.69 | BRD4 (0.41) | PDE10AADORA1PLA2G2A | |
| SCHEMBL638729 | 0.69 | PLA2G2A (0.43) | ADORA1PLA2G2A | |
| SCHEMBL2287588 | 0.68 | MAPT (0.37) | FFAR1FGFR1FGFR4MAPTPTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119675-B2 | Benzimidazole derivatives | MERCK PATENT GMBH (DE) | 2012-02-21 | — | — | US | claimed |
| EP-2121627-B1 | BENZIMIDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2010-08-18 | — | — | EP | claimed |
| US-20100016372-A1 | Benzimidazole Derivatives | MERCK PATENT GMBH (DE) | 2010-01-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016372-A1 | Benzimidazole Derivatives | GPR119, GLP1R, H1-3 | FFAR1 700/4885FGFR1 708/4885FGFR2 1912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.